- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07291427
Embolisation de l'hématome sous-dural chronique avec des coils détachables (SEED)
Sécurité et efficacité de l'embolisation des hématomes sous-duraux chroniques avec des spirales détachables
This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sukaina Davdani
- Numéro de téléphone: (212) 241-2524
- E-mail: Sukaina.Davdani@mountsinai.org
Sauvegarde des contacts de l'étude
- Nom: Sydney Edwards
- Numéro de téléphone: (212) 241-2524
- E-mail: Sydney.Edwards@mountsinai.org
Lieux d'étude
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85711
- Pas encore de recrutement
- Carondelet Neurological Institute
-
Chercheur principal:
- Alexander Coon, MD
-
Contact:
- Matthew Pohlmeyer
- E-mail: Matthew.Pohlmeyer@tenethealth.org
-
-
California
-
San Deigo, California, États-Unis, 92093
- Pas encore de recrutement
- University of California - San Deigo
-
Contact:
- Pete Chase
- E-mail: PChase@Health.UCSD.edu
-
Chercheur principal:
- David Santiago-Dieppa, MD
-
Walnut Creek, California, États-Unis, 94598
- Recrutement
- John Muir Health
-
Chercheur principal:
- Benjamin Yim, MD
-
Contact:
- Melenie Aaron
- E-mail: Melenie.Aaron@JohnMuirHealth.com
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40292
- Pas encore de recrutement
- University of Louisville
-
Contact:
- Mechelle Kaufman
- E-mail: Mechelle.Kaufman@louisville.edu
-
Chercheur principal:
- Isaac Josh Abecassis, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Pas encore de recrutement
- Oklahoma University Medical Center
-
Chercheur principal:
- Hakeem Shakir, MD
-
Contact:
- Michael Omimi
- E-mail: Michael-Omini@OU.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment
La description
Inclusion criteria:
- Age ≥ 18
- Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
- A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
- Signed informed consent obtained by patient or Legal Authorized Representative (LAR)
Exclusion criteria:
- Primary acute SDH
- Prior MMAE in target territory
- Premorbid mRS > 3
- Common carotid stenosis >70% or prior carotid stent placement
- Significant medical contraindication to angiography (kidney failure/disease)
- Anatomical variations that would make MMA embolization difficult or unsafe
- Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
- Pregnancy
- Life expectancy ≤ 1 year
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Participants with cSDH
All participants enrolled will be treated with the Balt coils.
|
MMA embolization utilizing Balt Coils
Autres noms:
surgical or bedside evacuation pre or post-surgical debridement |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in hematoma volume
Délai: 180 days
|
Change in hematoma volume based on CT imaging |
180 days
|
|
Change in maximal thickness
Délai: 180 days
|
Change in maximal thickness based on CT imaging |
180 days
|
|
Change in midline shift
Délai: 180 days
|
Change in midline shift (mm) based on CT imaging |
180 days
|
|
Number of periprocedural major disabling stroke or any death
Délai: 30 days
|
Number of periprocedural major disabling stroke or any death |
30 days
|
|
Number of participants with symptomatic recurrence progression requiring retreatment
Délai: 180 days
|
Number of participants with symptomatic recurrence progression of the SDH requiring retreatment |
180 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
Délai: 180 days
|
Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor |
180 days
|
|
Number of Acute successful embolization of the target vessel
Délai: Immediately post-procedure
|
Determination of successful embolization based on angiographic imaging |
Immediately post-procedure
|
|
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
Délai: 180 days
|
The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL. |
180 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Christopher Kellner, Icahn School of Medicine at Mount Sinai
- Chercheur principal: Benjamin Yim, John Muir Health
- Chercheur principal: Alexander Coon, Carondelet Neurological Institute
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Blessures et Blessures
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Hémorragie
- Traumatisme crânio-cérébral
- Traumatisme, système nerveux
- Hémorragies intracrâniennes
- Hémorragie intracrânienne, traumatique
- Conditions pathologiques, signes et symptômes
- Hématome
- Hématome sous-dural
- Hématome, sous-dural, chronique
Autres numéros d'identification d'étude
- STUDY-25-01365
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .